These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

808 related items for PubMed ID: 27742267

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.
    Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M.
    Am J Kidney Dis; 2014 Oct; 64(4):633-7. PubMed ID: 24656451
    [Abstract] [Full Text] [Related]

  • 24. Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study.
    Bamhraz AA, Rahim KA, Faqeehi HY, Alanazi A.
    Kidney Blood Press Res; 2020 Oct; 45(6):939-954. PubMed ID: 33238263
    [Abstract] [Full Text] [Related]

  • 25. [Atypical hemolytic uremic syndrome with C3 p.I1157T missense mutation successfully treated with eculizumab].
    Okano M, Matsumoto T, Nakamori Y, Ino K, Miyazaki K, Fujieda A, Sugimoto Y, Tawara I, Yamaguchi M, Ohishi K, Miwa H, Masuya M, Wada H, Katayama N.
    Rinsho Ketsueki; 2018 Oct; 59(2):178-181. PubMed ID: 29515070
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Genetics and outcome of atypical hemolytic-uremic syndrome in Turkish children: a retrospective study between 2010 and 2017, a single-center experience.
    Conkar S, Mir S, Berdeli A.
    Iran J Kidney Dis; 2019 Sep; 13(5):316-321. PubMed ID: 31705748
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
    Fakhouri F, Fila M, Provôt F, Delmas Y, Barbet C, Châtelet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, Frémeaux-Bacchi V.
    Clin J Am Soc Nephrol; 2017 Jan 06; 12(1):50-59. PubMed ID: 27799617
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome.
    Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar NCAJ, Wetzels JFM.
    Nephrol Dial Transplant; 2018 Apr 01; 33(4):635-645. PubMed ID: 29106598
    [Abstract] [Full Text] [Related]

  • 34. Defining treatment duration in atypical hemolytic uremic syndrome in adults: a clinical and pathological approach.
    Laurence J.
    Clin Adv Hematol Oncol; 2020 Apr 01; 18(4):221-230. PubMed ID: 32628650
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment.
    Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H.
    J Nephrol; 2017 Feb 01; 30(1):127-134. PubMed ID: 26995002
    [Abstract] [Full Text] [Related]

  • 37. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T, Watarai Y, Futamura K, Okada M, Tsujita M, Hiramitsu T, Goto N, Narumi S, Takeda A, Kobayashi T.
    Transplant Proc; 2017 Feb 01; 49(1):159-162. PubMed ID: 28104125
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury.
    Cao M, Leite BN, Ferreiro T, Calvo M, Fernández C, Alonso Á, Rodriguez A, Salvador P, Seijo R, Pita S, Arjona E, Rodríguez de Córdoba S, Valdés Cañedo F.
    Am J Nephrol; 2018 Feb 01; 48(3):225-233. PubMed ID: 30205388
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.